AAM
PCRX icon

Advisors Asset Management’s Pacira BioSciences PCRX Stock Holding History

Advisors Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,733
Closed -$43.1K – 1525
2025
Q1 		$43.1K Sell
1,733
-896
-34% -$21.5K ﹤0.01% 1300
2024
Q4 		$49.5K Sell
2,629
-2,179
-45% -$38.3K ﹤0.01% 1318
2024
Q3 		$72.4K Sell
4,808
-399
-8% -$6.82K ﹤0.01% 1265
2024
Q2 		$149K Sell
5,207
-1,081
-17% -$30.8K ﹤0.01% 1156
2024
Q1 		$184K Sell
6,288
-283
-4% -$8.69K ﹤0.01% 1148
2023
Q4 		$222K Sell
6,571
-100
-1% -$2.93K ﹤0.01% 1097
2023
Q3 		$205K Buy
6,671
+1,840
+38% +$66.3K ﹤0.01% 1107
2023
Q2 		$194K Buy
4,831
+710
+17% +$29.4K ﹤0.01% 1124
2023
Q1 		$168K Buy
4,121
+462
+13% +$18.4K ﹤0.01% 1146
2022
Q4 		$141K Buy
3,659
+2,402
+191% +$117K ﹤0.01% 1183
2022
Q3 		$67K Buy
1,257
+309
+33% +$17.2K ﹤0.01% 1325
2022
Q2 		$55K Buy
+948
New +$62.1K ﹤0.01% 1361

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Advisors Asset Management's PCRX Position: Q2 2025 in Review

Advisors Asset Management sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 1,733 shares — an estimated $43.1K sold.

Advisors Asset Management first reported a position in PCRX in Q2 2022 and held it in 12 quarters. The position peaked at $222K in Q4 2023. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

  • Advisors Asset Management reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
  • Advisors Asset Management sold 1,733 Pacira BioSciences shares in Q2 2025, an estimated $43.1K.
  • Advisors Asset Management first reported a position in Pacira BioSciences in Q2 2022 and held it in 12 quarters.
  • Advisors Asset Management's Pacira BioSciences position peaked at $222K in Q4 2023.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on Advisors Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.